FIELD: chemistry.
SUBSTANCE: invention relates to a compound of formula (II) and its crystalline form A, in which the X-ray powder diffraction pattern contains characteristic diffraction peaks at following angles 2θ: 3.30±0.20°, 6.33±0.20°, 6.55±0.20°, 10.62±0.20°, 12.57±0.20° and 13.11±0.20°, and crystalline form B, in which the X-ray powder diffraction pattern contains characteristic diffraction peaks at following angles 2θ: 12.12±0.20°, 16.48±0.20°, 16.95±0.20°, 17.94±0.20° and 21.87±0.20°. Invention also relates to a method of producing crystalline form B of a compound of formula (II), comprising (a) adding crystalline form A of the compound of formula (II) to a solvent to form a suspension; and (b) stirring suspension at 50 °C for 3 hours, filtering and drying, wherein the solvent is selected from a group consisting of isopropanol, tetrahydrofuran, acetonitrile, 2-butanone and ethyl acetate. According to the invention, the compound of formula (II) is used in preparing a drug for treating glaucoma or ocular hypertension.
EFFECT: invention discloses a salt form of an isoquinolinone type compound as an ROCK inhibitor and a method for preparing said compound.
17 cl, 7 dwg, 11 tbl, 9 ex
Authors
Dates
2024-06-26—Published
2021-12-21—Filed